公开(公告)号：US20060255752A1

公开(公告)日：2006-11-16

申请号：US10560213

申请日：2003-11-07

申请人： Kwok Chow ,  Tan Ngo ,  Yu Jiang ,  Lin Ni

发明人： Kwok Chow ,  Tan Ngo ,  Yu Jiang ,  Lin Ni

IPC分类号： H05B39/00

CPC分类号： H05B33/0842 ,  H05B33/0803

摘要： A flash driving apparatus that eliminates the limitation of setting the flash condition as required of the prior art is provided in the utility model, including a power supply, a control IC, a flash member and a switch module, wherein the switch that is connected with the trigging pin TG of the control IC is provided with two or more contacts, and a condition recognizer that will switch into conduction or cutoff according to a given condition is connected between the switch and the trigging pin TG; With this configuration, when the movement of the switch between the two contacts meets the condition set in the condition recognizer, the condition recognizer switches into conduction and sends the trigging signal to the control IC, or alternatively, the condition recognizer switches into cutoff and stops sending the trigging signal to the control IC such that the apparatus produces the effect of flash when the vibration of the switch meets the given condition.

摘要翻译： 本实用新型提供了一种消除在现有技术中设定闪光条件的限制的闪光驱动装置，包括电源，控制IC，闪光部件和开关模块，其中与 控制IC的触发销TG设置有两个或更多个触点，并且根据给定条件切换到导通或截止的条件识别器连接在开关和触发引脚TG之间; 利用这种配置，当两个触点之间的开关的移动满足条件识别器中设置的条件时，条件识别器切换到导通并将触发信号发送到控制IC，或者，条件识别器切换到截止和停止 将触发信号发送到控制IC，使得当开关的振动满足给定条件时，该装置产生闪光的效果。

公开(公告)号：US20170065526A1

公开(公告)日：2017-03-09

申请号：US15259039

申请日：2016-09-07

申请人： Shaoping Wang ,  Xin Liu ,  Meng Wang ,  Weining Yang ,  Kwok Chow

发明人： Shaoping Wang ,  Xin Liu ,  Meng Wang ,  Weining Yang ,  Kwok Chow

IPC分类号： A61K9/20 ,  A61K31/5377 ,  A61K9/28 ,  A61K9/00

CPC分类号： A61K9/2095 ,  A61K9/1694 ,  A61K9/2833 ,  A61K31/5377 ,  B01J2/04 ,  B01J2/14

摘要： The present invention discloses a pharmaceutical composition that includes rivaroxaban and one or more excipient in a solid dosage form and methods for making the same. Methods for making compositions of the present invention includes powderizing rivaroxaban by centrifugal wet granulation to form compositions suitable for solid oral dosage form. Pharmaceutical dosage forms produced by methods of the present invention are more homogenous, smoother, and have better rheological properties, better compressibility, and much easier to make. They are much lower in cost and also easier to produce at industrial scales.

摘要翻译： 本发明公开了一种药物组合物，其包含利伐沙班和一种或多种固体剂型赋形剂及其制备方法。 制备本发明组合物的方法包括通过离心湿法制粒粉碎利伐沙班以形成适合于固体口服剂型的组合物。 通过本发明方法制备的药物剂型更均匀，更平滑，并且具有更好的流变性能，更好的压缩性，并且更易于制备。 它们的成本要低得多，在工业规模上也更容易生产。

公开(公告)号：US20100151019A1

公开(公告)日：2010-06-17

申请号：US12618511

申请日：2009-11-13

申请人： Chandir Ramani ,  Juan Wang ,  Anil Kane ,  Kwok Chow ,  Joe Lambing

发明人： Chandir Ramani ,  Juan Wang ,  Anil Kane ,  Kwok Chow ,  Joe Lambing

IPC分类号： A61K9/22 ,  A61K31/517 ,  A61P9/00 ,  A61P7/02

CPC分类号： A61K47/38 ,  A61K9/0002 ,  A61K9/0065 ,  A61K9/2009 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/2027 ,  A61K9/2031 ,  A61K9/205 ,  A61K9/2054 ,  A61K47/10

摘要： A novel solid composition and methods for making and using the solid composition are provided. The solid composition comprises: (a) at least one active agent with a solubility of less than about 0.3 mg/ml in an aqueous solution with a pH of at most about 6.8 at a temperature of about 37° C.; and (b) a hydrophilic polymer matrix composition comprising: i) a hydrophilic polymer selected from the group consisting of METHOCEL™, POLYOX™ WSR 1105 and combinations thereof; and optionally ii) a hydrophobic polymer selected from the group consisting of Ethocel 20 premium; and (c) an alkalizer selected from the group consisting of calcium carbonate, magnesium oxide heavy and sodium bicarbonate; wherein the composition provides at least about 70% release of the active between about 7 to about 12 hours following oral administration.

摘要翻译： 提供了一种新颖的固体组合物和制备和使用该固体组合物的方法。 固体组合物包含：（a）至少一种在约37℃的温度下pH至多约6.8的水溶液中具有小于约0.3mg / ml的溶解度的活性剂; 和（b）亲水性聚合物基质组合物，其包含：i）选自METHOCEL TM，POLYOX TM WSR 1105及其组合的亲水性聚合物; 和任选地ii）选自Ethocel 20溢价的疏水性聚合物; 和（c）选自碳酸钙，氧化镁重质和碳酸氢钠的碱化剂; 其中所述组合物在口服给药后提供约7至约12小时之间的至少约70％的活性释放。